Editorial: Whither HER2-Related Therapeutics? (breast cancer) -- Journal of Clinical Oncology Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, February 24, 2010

Editorial: Whither HER2-Related Therapeutics? (breast cancer) -- Journal of Clinical Oncology



Note: references to solid tumours

"Evidence suggests that most solid tumors, regardless of their type, cannot grow beyond approximately 1 mm3 until they establish a blood supply by inducing new blood vessels from existing host capillaries, called tumor-induced angiogenesis......It follows then that tumor cells with low HER3 mRNA are more likely to respond to pertuzumab, given that these are the cells where the pathway is activated. We would conjecture that this signature does not apply exclusively in ovarian cancer, but may also be found in other solid tumors, such as non–HER2-positive breast, colorectal, and so on."

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.